25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue

Lancet

Volumn 357, Issue 9269, 2001, Pages 1673-1674

  Tangpricha, Vin ^a   Flanagan, John N ^a   Whitlatch, Lyman W ^a   Tseng, Chi C ^b   Chen, Tai C ^a   Holt, Peter R ^c   Lipkin, Martin S ^d   Holick, Michael F ^a  

^a Vitamin D   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c St Luke's Roosevelt Hospital Center ^*  (United States)

^d WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; KIDNEY ENZYME; MESSENGER RNA; VITAMIN D;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; GROWTH REGULATION; HUMAN; HUMAN TISSUE; HYDROXYLATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SUNLIGHT; VITAMIN D DEFICIENCY;

EID: 0035954020     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04831-5     Document Type: Article

References (5)

1. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study
2. Do sunlight and vitamin D reduce the likelihood of colon cancer?
3. 3-1alpha-hydroxylase activity and regulation of side-chain metabolism
4. Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo
5. Serum 25 hydroxyvitamin D3 inhibits proliferation of colonic epithelial cells in subjects at high risk for colon neoplasia